Dr. François Marceau has been studying bradykinin receptors for over 30 years, their regulation, ligands and functions. Notably, as early as in the 1980s, the regulation of B1 receptor expression by cytokines and immunopathology was highlighted, with work replicated and expanded around the world. He has been part of an international committee on the nomenclature of bradykinin receptors, leading to a review article cited over 800 times, of which he is a co-author (Pharmacol Rev. 2005; 57: 27). More recently, two subjects have caught the attention of the laboratory, i.e. the creation of bifunctional biotechnological ligands for peptide hormone receptors, including those of bradykinin, and the angioedema states, presently the main clinical application of bradykinin. Dr. Marceau has been, and is, regularly invited as a speaker at specialized conferences.
2705, boulevard Laurier
Canada G1V 4G2
Data not available
Species-specific pharmacology of maximakinin, an amphibian homologue of bradykinin: putative prodrug activity at the human B2 receptor and peptidase resistance in rats.Journal Article
PeerJ, 5 , pp. e2911, 2017.
S100A9 potentiates the activation of neutrophils by the etiological agent of gout, monosodium urate crystals.Journal Article
J Leukoc Biol, 102 (3), pp. 805-813, 2017, ISSN: 0741-5400.
Infrared-emitting, peptidase-resistant fluorescent ligands of the bradykinin B2 receptor: application to cytofluorometry and imaging.Journal Article
BMC Res Notes, 9 (1), pp. 452, 2016.
Lysosomotropic cationic drugs induce cytostatic and cytotoxic effects: Role of liposolubility and autophagic flux and antagonism by cholesterol ablation.Journal Article
Toxicol Appl Pharmacol, 305 , pp. 55-65, 2016, ISSN: 0041-008X.
Editorial: Improving the data reproducibility and general interest of natural product submissions.Journal Article
Int Immunopharmacol, 37 , pp. 3-4, 2016, ISSN: 1567-5769.
Introduction: Natural product-based drug discovery in Immunopharmacology.Journal Article
Int Immunopharmacol, 37 , pp. 1-2, 2016, ISSN: 1567-5769.
The isolated human umbilical vein as a bioassay for kinin-generating proteases: An in vitro model for therapeutic angioedema agents.Journal Article
Life Sci, 155 , pp. 180-8, 2016, ISSN: 0024-3205.
Biotechnological Fluorescent Ligands of the Bradykinin B1 Receptor: Protein Ligands for a Peptide Receptor.Journal Article
PLoS ONE, 11 (2), pp. e0148246, 2016.
Pharmacological profile of a bifunctional ligand of the formyl peptide receptor1 fused to the myc epitope.Journal Article
Int Immunopharmacol, 25 (1), pp. 229-34, 2015, ISSN: 1567-5769.
Pharmacological effects of recombinant human tissue kallikrein on bradykinin B2 receptors.Journal Article
Pharmacol Res Perspect, 3 (2), pp. e00119, 2015, ISSN: 2052-1707.
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
Recently finished projects
- Caractérisation du système kallikréine-kinines chez les familles de patients atteints d'angio-œdème héréditaire avec niveau normal de " C1-esterase inhibitor", Subvention, Fondation du CHU de Québec, from 2019-05-31 to 2020-03-31